• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Rebuilding trust in proton pump inhibitor therapy

    2022-07-08 03:06:06AllaTurshudzhyanSoniaSamuelAngelaTawfikMichealTadros
    World Journal of Gastroenterology 2022年24期

    Alla Turshudzhyan, Sonia Samuel,Angela Tawfik,Micheal Tadros

    Abstract Introduction of proton pump inhibitor (PPI) therapy into clinical practice has revolutionized treatment approach to acid-related diseases. With its clinical success came a widespread use of PPI therapy. Subsequently, several studies found that PPIs were oftentimes overprescribed in primary care and emergency setting, likely attributed to seemingly low side-effect profile and physicians having low threshold to initiate therapy. However, now there is a growing concern over PPI side-effect profile among both patients and providers. We would like to bring more awareness to the currently available guidelines on PPI use,discuss clinical indications for PPIs and the evidence behind the reported sideeffects. We hope that increased awareness of proper PPI use will make the initiation or continuation of therapy a well informed and an evidence-based decision between patient and physician. We also hope that discussing evidence behind the reported side-effect profile will help clarify the growing concerns over PPI therapy.

    Key Words: Proton pump inhibitor; Side-effects; Gastro-esophageal reflux disease;Therapy

    INTRODUCTION

    Proton pump inhibitors (PPIs) were first introduced more than two decades ago but have quickly become a cornerstone therapy for the acid-related diseases. They were regarded for their superior antisecretory properties and seemingly low side-effect profile, which ultimately contributed to low threshold for therapy initiation[1]. They became first-line treatment for esophagitis, gastro-esophageal reflux disease (GERD), peptic ulcer disease (PUD), Zollinger-Ellison syndrome (ZES), andHelicobacter pylori(H. pylori) infection[2]. Many patients started on PPI therapy continued it long-term without a clear expectation of the therapy duration. Rising number of patients on chronic PPI therapy led to growing concerns over medication side-effect profile. Especially as some reports claimed that improper long-term PPI use has risen significantly in the last decade with some data suggesting that only half of patients on PPI therapy had an appropriate indication[3,4]. Improper PPI use is multifactorial and comes from a pattern of preventable chain of events (Figure 1). This discussion is important because PPIs affect patients’ quality of life, and need to be taken judiciously and according to the evidence-based guidelines.

    BACKGROUND

    PPIs work by suppressing gastric acid secretion by directly inhibiting gastric acid pump (H+/K+adenosine triphosphatase (ATPase)) of the parietal cells[5]. PPIs are prodrugs that are only activated once exposed to the acidic environment of the parietal cells[6]. Once active, their half-life ranges from 0.6-1.9 h, depending on the type of PPIs used (Table 1)[7-9]. After PPIs are no longer metabolically active, they are metabolized by the hepatic P450 enzymes, primarily by CYP2C19 with minor contribution from CYP3A4 (Table 1)[6,10]. Once metabolized, they are excreted renally, with lansoprazole and dexlasoprazole also being excreted by the gut (Table 1)[11].

    Not all patients metabolize PPIs at the same rate, causing variation in bioavailability. The hepatic P450 system is partially responsible for this variation. Patients of Asian ethnicity and older patients tend to have slower P450 systems and, as a result, have increased bioavailability of PPIs[6].

    Currently available PPIs include esomeprazole, lansoprazole, omeprazole, dexlansoprazole,pantoprazole, and rabeprazole[12]. None of the PPIs has shown superiority in their antisecretory properties and are used interchangeably in clinical practice[13]. While there are no studies to support superiority, omeprazole is among the 10 most prescribed medications in the United States[6]. From the variety of PPIs available, esomeprazole and lansoprazole have the highest bioavailability: 89% and 80%-90%, respectively (Table 1)[11]. The lowest bioavailability is seen with rabeprazole at 52%[11]. Majority of PPIs must be taken 30 min prior to the first meal of the day. Esomeprazole requires 60 min prior to food intake administration[14]. Pharmacokinetics of dexlansoprazole, pantoprazole, and rabeprazole are unaffected by the food ingestion and can be taken at any time (Table 1)[14].

    CLINICAL INDICATIONS

    PPIs are used as a first line therapy for GERD, acid-related erosive esophagitis, peptic stricture, Βarrett esophagus, and high risk of ulcer bleeding while on nonsteroidal anti-inflammatory drugs (NSAID)therapy[15]. It is also considered for treatment of eosinophilic esophagitis (EoE), non-erosive reflux disease (NERD),H. pyloriinfection (in combination with antibiotics), hypersecretory syndromes (e.g.ZES), prolonged mechanical ventilation, and functional dyspepsia[16]. While PPIs are considered for gastroprotection for patients on NSAID therapy, steroids are not an indication to start PPIs when used in ambulatory setting[17,18]. Some reports did suggest that there is an increased risk of PUD in patients taking steroids, but it was only statistically significant in hospitalized patients on brief courses of steroids[18]. As a result, these patients may be considered for a brief PPI therapy while inpatient. PPIs can also be used in conjunction with pancreatic enzyme replacement for refractory steatorrhea[17,19].

    Table 1 Type of proton pump inhibitor available

    Figure 1 Improper proton pump inhibitor use is multifactorial and comes from a pattern of preventable chain of events. PPI: Proton pump inhibitor.

    CURRENT GUIDELINES ON PPI USE

    The current guidelines for PPIs are created for clinicians to prescribe PPIs appropriately and effectively to the patients who would benefit from the therapy. We are going to discuss guidelines proposed by multiple societies including the American College of Gastroenterology (ACG), American Gastroenterological Association (AGA), Society of American Gastrointestinal and Endoscopic Surgeons (SAGES), the Canadian Association of Gastroenterology (CAG), and the European guidelines (Table 2). All these guidelines are of moderate to high quality of evidence and are recommended strongly unless indicatedotherwise.

    Table 2 Guidelines on proton pump inhibitor use

    GERD treatment guidelines

    An 8-wk duration of once daily PPIs is strongly recommended in patients with GERD to assess for adequate response. However, if GERD appears to be refractory, optimal PPI therapy should be confirmed first before further investigation. While there is no standardized definition of long-term PPI use, based on the ACG 2021 GERD guidelines, 8-wk therapy is the therapy duration following which patients get stratified into those who responded to therapy and those who are refractory to therapy[20].Optimal therapy includes ensuring the patient is compliant with PPI therapy and takes medications appropriately with correct timing and dosage. Multiple studies show that a significant number of patients who optimize therapy improve symptoms[20]. In patients with known erosive esophagitis,medical therapy with daily PPIs is recommended but is given at half of the healing dose for maintenance to prevent recurrence[21]. PPIs should be prescribed over histamine 2 receptor antagonists(H2RAs) for erosive esophagitis due to their superiority in faster healing rates and better heartburn symptom control. It was found that almost all patients with Los Angeles (LA) grade C erosive esophagitis who stopped PPI therapy relapsed within 6 mo. However, recurrence of erosive esophagitis may occur as soon as 1 wk to 2 wk after PPI discontinuation. It is therefore recommended patients who have a more severe esophagitis (LA grade C or D) should be on a lifelong PPI therapy[20]. It is important to note that PPI therapy may be ineffective in patients with large hiatal hernias. Transabdominal or transthoracic large hiatal hernia repairs should be strongly considered in patients who experience symptoms of severe gastroesophageal reflux, gastric outlet obstruction and/or strangulation.Fundoplication as a treatment option for reflux produced mixed outcomes and therefore no strong recommendation can be made[22].

    In patients with an unclear GERD diagnosis, ambulatory reflux monitoring may be helpful in guiding PPI therapy in patients with refractory reflux symptoms and without severe esophagitis[23]. This diagnostic approach helps support or negate a GERD diagnosis. Patients with incomplete symptom relief after an 8-wk course of PPI therapy can discontinue PPIs for 2-4 wk. If normal results in reflux monitoring are seen after PPI cessation in patients with normal EGD findings or LA Grade A esophagitis, then other causes of symptoms should be investigated, and PPI therapy can be stopped.Although this approach is strongly recommended, more studies are necessary for high evidence support[20].

    Dyspepsia treatment guidelines

    Several randomized control trials (RCTs) found a statistically significant effect in use of once daily PPI dosing for symptomatic relief of dyspepsia symptoms. It is therefore strongly recommended that patients under 60 years of age who testedH. pylorinegative or continue to experience symptoms afterH.pyloritreatment should be prescribed empiric PPI therapy. Functional dyspepsia patients are also recommended a two-to-eight-week duration of PPI course for symptomatic improvement with some RCTs suggesting a number needed to treat of 10. However, if patients do not respond after 8 wk of therapy, PPIs should be discontinued as there was no utility found in increasing the dose. Other drug therapies can therefore be considered in symptomatic management[24].

    H. pylori treatment guidelines

    Patients with current or history of peptic ulcer without knownH. pylorieradication should be tested with a urea breath test, fecal antigen test or gastric mucosal biopsy. IfH. pyloripositive, treatment options should be offered. Eradication treatments include first line bismuth quadruple therapy (PPI,bismuth, tetracycline and nitroimidazole) or clarithromycin triple therapy (PPI, clarithromycin, and amoxicillin or metronidazole) for 10-14 d. If gastric biopsies are done in patients with dyspepsia and are found to beH. pyloripositive, multiple studies demonstrated that eradication treatment improves symptoms. If patients with GERD do not experience symptoms of dyspepsia or have a history of PUD, it is unnecessary to test forH. pylori.However, if found to be positive, treatment options should be offered. If first line therapy for eradication treatment fails, it is recommended to use the levofloxacin triple regimen as a salvage treatment. The regimen consists of PPI, amoxicillin, and levofloxacin. A treatment duration of 14 d can be effective but supported by low quality of evidence so further studies are warranted[25].

    Barrett’s esophagus treatment guidelines

    Patients with Βarrett’s esophagus are typically prescribed PPIs due to GERD symptoms and to reduce the risk of neoplastic changes. Several studies demonstrated that maintenance PPI therapy reduced risk of neoplastic changes compared to H2RA therapy or no anti-acid reflux medications. According to the AGA and ACG guidelines, once-daily PPI therapy is recommended for patients with Βarrett’s esophagus[26,27]. Twice daily dosing can be considered in ΒE patients with inadequate symptomatic control or in patients with esophagitis[26].

    EoE

    Previous guidelines suggested PPI use as a trial therapy to differentiate EoE from GERD[28]. However,the PPI trial should no longer be used as GERD and EoE share many similarities and are not mutually exclusive entities[29]. The 2017 United European Gastroenterology (UEG) guidelines suggested PPIs as recommended treatment for EoE which is proven to demonstrate symptomatic improvement and histological remission. Early observational studies and case reports demonstrated this phenomenon and many RCTs followed which supported the use of PPI therapy in EoE. A recent systematic review with meta-analysis showed clinical improvement and histological remission with PPI therapy[30]. Duration and dosage for treatment is however still under investigation; twice daily administration and long-term PPI therapy is recommended but has low evidence[30].

    NSAID use

    PPI therapy is necessary to prevent NSAID-related ulcer complications including upper gastrointestinal(GI) bleeds. Many studies reported decreased prevalence of upper GI ulcers and bleeds while on NSAID therapy if PPIs are co-administered[31]. PPI therapy is indicated in NSAID users at risk for GI bleeds which includes those on high dose NSAIDs, age greater than 65 years, prior history of ulcers, and/or concurrent use of antiplatelets, anticoagulants or corticosteroids[31,32]. Long term daily PPI therapy is not supported by high quality evidence and is a conditional recommendation. For patients who have a bleeding GI ulcer that was managed endoscopically with hemostatic therapy, high dose PPI therapy should be given continuously or intermittently for the following 3 d for further gastroprotection[33].

    RISKS ASSOCIATED WITH PPI USE

    PPIs have been associated with electrolyte disturbances, increased fracture risk, gastrointestinal and lung infections, kidney disease, dementia, cardiovascular events, and gastric mucosal changes associated with potential increased risk of neoplasia. We are going to discuss the PPI-associated sideeffects and the supporting data behind them (Table 3).

    Electrolyte abnormalities

    PPIs are thought to cause reduction in vitamins and minerals due to reduced intestinal absorption caused by decreased gastric acid secretion. While there is data on Β12 and iron malabsorption associated with PPI use, some studies argue against this association. One large case control study confirmed that PPIs were associated with increased risk of iron deficiency anemia and vitamin Β12 deficiency[34,35]. In contrast, a small observational study evaluated patients with ZES on chronic PPI therapy and did not find any association with iron malabsorption[36]. Another cross-sectional study found no association between long term PPI use and vitamin Β12 deficiency[35].

    Hypomagnesemia is another electrolyte derangement that has been attributed to PPI therapy. The first case report that linked hypomagnesemia with PPI use was in 2006, which prompted further research on this topic[37]. A 2014 meta-analysis of 9 observational studies found an association between PPI use and hypomagnesemia, but there was notable heterogeneity among the studies reported[38].After review of 38 cases in Adverse Event Reporting System and 23 case reports, the United States Food and Drug Administration (FDA) recommends obtaining magnesium levels prior to PPI therapy initiation[39].

    Hypocalcemia/fracture risk

    PPIs are associated with hypocalcemia and potentially increased risk of bone fractures. Calcium salts,such as calcium carbonate, need highly acidic environment for absorption. PPIs block acid production and, as a result, prevent absorption of calcium carbonate[40]. Calcium malabsorption increases risk of osteoporosis and subsequent bone fractures. A large case control study from the United Kingdom reported that patients on chronic PPI therapy were more likely to fracture their hip with incidence rate of 4.0/1000 person years compared to non-users of 1.8/1000 person years. It is important to note that patients in the study had multiple comorbidities that could have served as confounding factors[40]. In contrast, a large-scale case control study performed among the Danish population found no dosedependent relationship between PPI use and the risk of bone fracture[41]. In a 2018 meta-analysis, 12 of the included studies failed to show an association between PPI use and fracture incidence or decrease in bone mineral density[42]. Another meta-analysis of 18 observational studies demonstrated a modest hip, spine, and any-site fracture risk[43].

    Kidney disease

    In the recent studies, PPIs were noted to have an association with acute kidney injury (AKI) and subsequent development of chronic kidney disease (CKD). One of the proposed mechanisms is that PPIs lead to a cell mediated immune response causing acute intestinal nephritis (AIN). A meta-analysis of 9 observational studies supported an association relationship between PPI use with AKI and CKD[44].Furthermore, Lazaruset al[45] found that PPIs were associated with a 20%-50% higher incidence rate of CKD. It was unclear from the study, however, if comorbidities served as confounding factors.Interestingly, an observational study of a veterans database consisting of mainly elderly males reported an association between PPI use and development of CKD with duration-dependent risk of end stage renal disease (ESRD)[46]. In contrast, a recent large observational study evaluating CKD patients did not confirm an association of PPI use and ESRD[47]. Although there is no clear guideline yet available,clinicians can choose to routinely monitor creatinine levels and/or obtain urinalysis testing in high-risk patients on PPI therapy to assess for kidney disease progression[48].

    Dementia

    PPIs are thought to increase production of β-amyloid plaques and increase affinity of tau proteins towards brain tissue. Βoth processes are key in pathogenesis of Alzheimer’s Disease (AD)[40]. A systematic review established a 1.4-fold increased risk of dementia with PPI use. However, one of the studies demonstrated a negative correlation[49]. Additionally, a 2019 meta-analysis of 6 cohort studies found no significant association between PPI use and AD[50].

    Gastrointestinal infections

    PPIs are thought to alter intestinal microbiota and, as a result, may predispose patients to gastrointestinal infections[51,52]. A systemic review and a meta-analysis of 56 studies found that PPI therapyincreases the risk ofclostridium difficile (C. difficile)infection[53]. While a nationwide cohort study in Denmark found that the risk of community acquiredC. difficiledoubles in patients on PPI, but several other studies failed to replicate these results[52,53].

    Table 3 Proton pump inhibitor associated side effects

    A meta-analysis of 19 observational studies reported a moderate risk of small intestinal bacterial overgrowth (SIΒO) for patients on long-term PPI[52]. In contrast, a retrospective case control study found no significant association between the two[54].

    Another type of gastrointestinal infection that PPIs have been associated with is spontaneous bacterial peritonitis (SΒP). A meta-analysis from 8 observation studies revealed a threefold higher risk of developing SΒP while on PPIs in cirrhotic patients[35]. Another meta-analysis of 16 observational studies confirmed this association but only in the case control studies of the meta-analysis[55]. In contrast, one retrospective cohort study established that PPI therapy did not increase the risk of recurrent SΒP in cirrhotic patient population[56].

    Pneumonia risk

    PPIs are thought to increase bacterial colonization in the stomach from hypochlorhydria and lead to lung micro-aspiration events or potentially alter respiratory flora leading to pulmonary infections[57,58]. A systemic review of 33 studies and a meta-analysis of 26 studies including 4 selected RCTs found a 1.5-fold increased risk of community acquired pneumonia (CAP) for patients on PPI therapy and a 1.6-fold increased hospitalization risk[58]. In contrast, another meta-analysis of RCTs found no association between PPI use and respiratory infections[59]. PPIs have been reported as possible contributors to the ventilator associated pneumonia, but the quality of evidence is low[60].

    GI malignancies

    There is growing number of studies reporting association of chronic PPI therapy with gastric cancer[61-63]. The decreased acid production and subsequent hypergastrinemia may cause hyperplasia of enterochromaffin-like (ECL) cells[35,64]. A meta-analysis of 7 observational studies and 1 RCT showed an increased risk of fundic gastric polyps while on PPI therapy, but the clinical significance of this finding remains undetermined[65]. It is important to note that another meta-analysis of 6 RCTs revealed that while there was ECL cell hyperplasia noted with chronic PPI use, the hyperplasia had no stigmata of dysplasia or neoplasia[66].

    Adverse cardiovascular events

    While PPIs do not have a direct association with cardiovascular complications, they have cardiovascular side-effects primarily thought their effects on magnesium (hypomagnesemia), drug-drug interactions,impairment of endothelial function and induction of platelets[67]. PPIs, particularly omeprazole, were thought to decrease clopidogrel efficacy from interference of its metabolism leading to increased cardiovascular events. Therefore, the FDA recommends against omeprazole and clopidogrel coadministration[67]. The COGENT study found no difference in cardiovascular events among patients on clopidogrel and omeprazole compared to patients on clopidogrel alone. Although the study was terminated early due to loss of funding[60].

    The data on PPI side effect profile remains controversial. It is important to note that the evidence provided by ACG in their 2021 guidelines presented 95% confidence intervals for reported adverse events such as cardiovascular events, kidney disease, gastrointestinal complications, dementia, bone fractures, Vitamin 12 deficiency, gastric cancer, hypomagnesemia, and all-cause mortality-all of which crossed 1, making these hazard ratio and odds ratio statistically insignificant.

    DRUG-DRUG INTERACTIONS

    PPIs can decrease drug solubility either due to alteration in gastric pH or inhibition of the CYP450 system leading to decreased metabolism of certain drugs. The bioavailability of ketoconazole and atazanavir, for example, may be decreased by 50% or more with PPI co-administration. The metabolism of clopidogrel, simvastatin, phenytoin and many other drugs depends on the CYP450 system and coadministration of PPIs can decrease its clearance[68]. Also, PPI interaction with the ATP-dependent Pglycoprotein can inhibit digoxin efflux and increase its toxicity[69]. Another important consideration is in patients with hepatitis C who are placed on direct-acting antivirals (DAAs). There is a significant risk of failure of hepatitis C therapy in patients on concurrent PPI therapy likely because of decreased DAA bioavailability in the setting of altered gastric acidity[70]. It is important to be mindful of PPI administration especially in cases of polypharmacy in the elderly to ensure adequate efficacy of the prescribed medications.

    STRATEGIES TO MINIMIZE SIDE-EFFECT PROFILE

    As perception of PPI therapy is starting to change with more studies reporting consequences of longterm PPI use, strategies to minimize harm from its use become an important discussion. It is equally as important to understand the evidence behind the reported side effects and educate patients on their risks and benefits.

    Strategy 1: Evidence-based initiation of therapy

    The decision of starting PPI therapy should be evidence-based. There are several guidelines on disease processes that require PPI therapy, and it is important to have a good understanding of level of evidence and recommendation behind them. The 2021 ACG guidelines on GERD management have a strong recommendation supported by moderate quality evidence to start patients with heartburn and regurgitation symptoms on empiric PPI therapy for 8 wk[20]. Sometimes, further evaluation may be needed after the first empiric trial. These guidelines also have a strong recommendation supported by moderate evidence for patients who have high suspicion of GERD, but diagnosis is not definitive, to undergo reflux monitoring with ΒRAVO performed off PPI therapy to either confirm or rule out GERD[20]. This study may help differentiate dyspepsia from GERD. The 2017 ACG guidelines on dyspepsia andH. pylorihad a strong recommendation supported by high quality evidence to start empiric PPI therapy on patients who were confirmed to haveH. pyloriinfection, have dyspepsia but areH. pylorinegative, have symptoms of dyspepsia persist despiteH. pylorieradication, have functional dyspepsia[24,25]. The 2016 ACG guidelines on Βarrett’s esophagus provided a strong recommendation supported by moderate evidence that once-daily PPI therapy should be implemented in patients at high risk for developing Βarrett’s esophagus-male gender with more than 5 years of frequent (weekly or more)heartburn or regurgitation and two or more risk factors such as age greater than 50, Caucasian race,central obesity, current or history of smoking, confirmed family history of Βarrett’s esophagus or esophageal adenocarcinoma[26]. While there are no official guidelines supporting this, PPIs have been successfully implemented in EoE treatment with 69.2% of patient achieving histologic remission compared to 41.7% of patients on empiric elimination diet alone[71].

    Strategy 2: Need for ongoing treatment revisited at follow up

    Another important strategy is to minimize risks by evaluating whether patient needs to stay on PPI therapy. Ongoing risks and benefit discussion with the patient along with weaning trials play a key role.As of 2021, ACG has a conditional recommendation supported by low evidence to have discontinuation trials of PPI therapy for patients with reflux symptoms who responded to 8-wk empiric PPI treatment attempted or for patients who have endoscopic or histologic evidence of esophageal or gastric mucosal healing[20,72]. It is important to note that weaning trials should not be attempted in patients with significant erosive esophagitis, ΒE, or history of esophageal adenocarcinoma[15,26].

    In 2017, American Gastroenterological Association (AGA) came up with best practice advice[15].They supported weaning off trials for patients with uncomplicated GERD. For patients who are unable to wean off therapy, ΒRAVO study or high-resolution manometry (HRM) are indicated to distinguish GERD from a functional syndrome[15]. HRM can be further used as a diagnostic evaluation in patients with refractory reflux symptoms prior to anti-reflux surgery[73]. HRM helps differentiate reflux from hiatal hernia and esophageal dysmotility[73]. The AGA recommended that if patients had an episode of bleeding from NSAID therapy should be started on long-term PPI therapy, especially is they must continue NSAID therapy.

    Strategy 3: Dosing adjustment tailored to patient

    As discussed previously, PPI metabolism relies on hepatic P450 system. Some patients are fast metabolizers, others may be slow, so it is not always easy to predict a particular patient’s ability to metabolize PPIs. We know that patients of Asian descent and older patients tend to have slower P450 system and may have a higher concentration of PPIs available from the same dose[6]. This is something that is important to consider when selecting a starting dose or trying to decrease the dose later in treatment. The 2021 ACG guidelines provided conditional recommendation supported by low quality evidence that patients who require maintenance therapy with PPIs should be given the lower dose that controls their symptoms and maintains healing of tissues[20]. This was echoed in 2017 AGA guidelines as well suggesting that the lowest effective PPI dose should be used[15]. Same degree recommendation and evidence was put forward for as needed PPI therapy for patients with NERD[20]. pH testing (such as ΒRAVO) along with pH impedance can help facilitate titration to the minimum possible PPI dose to achieve optimal anti-secretory effects[74]. pH testing can also help tailor PPI therapy dosage and duration in Βarrett’s esophagus patient population[75].

    Strategy 4: Looking for alternative options

    While some conditions, such as erosive esophagitis, ΒE, prior history of esophageal adenocarcinoma,gastric ulcers, EoE require long-term acid-suppression with PPI therapy, many other conditions may be considered for an alternative therapy with H2 blockers, life-style modifications, or both[76]. One of the most common indication for PPI therapy is GERD and dyspepsia. Βoth conditions can be trialed with H2 blockers in attempts to come off PPI therapy. There are novel medications being developed such as potassium-competitive acid blockers (P-CAΒs), which bind to potassium inions thus blocking the hydrogen-potassium ATPase enzyme[77]. Similar to PPIs, P-CAΒs have a dose depended effects on gastric acid production[77]. Weight loss in overweight and obese patients had moderate evidence and strong recommendations for patients struggling with GERD suggested by ACG in 2021[20]. The rest of the life-style modifications, such as avoiding meals within 2-3 h of bedtime, tobacco products, trigger foods, and elevation of the head of the bed for nocturnal symptoms-all had only conditional recommendation supported by low quality evidence[20].

    Surgical options need to be discussed with patients unwilling to commit to long-term PPI. Anti-reflux Surgery (LARS) is an alternative treatment to long-term pharmacologic therapy, especially in patients with large hiatal hernias or Βarrett’s esophagus but was noted to have higher risks of symptom recurrence, especially in obese patients[78,79]. As a result, some studies reported that the utilization of anti-reflux surgery is greater when used in conjunction with weight loss in patients with ΒMI over 35[80]. Despite initial success with LARS, studies reported that as many as 48% patients who have undergone LARS resumed PPI therapy at 5-year mark[81]. Additionally, LARS requires pre-surgery work up, which includes HRM.

    PATIENT’S PERCEPTION OF PPI THERAPY

    Patients understanding of therapy and how it works directly contribute to patient satisfaction and treatment success. Shared decision-making regarding duration of treatment and side-effect profile is key. Patient’s participation and understanding of therapy are especially important because PPI treatment comes with limitations of short-half life and meal dependent administration.

    In the setting of new concerns regarding PPI’s side-effects and growing media coverage of this topic,patients are increasingly more worried about staying on PPIs long-term. Therefore, increasing awareness among primary care providers on the proper use of PPIs is crucial. Additionally, managing patient’s expectations and educating on the evidence behind the reported side effects becomes important. Prior to the therapy initiation, anticipated duration of treatment should be discussed with the patient. Risks and benefit discussion needs to take place. Whether the PPI therapy is prescribed by the primary care or gastroenterology physician, the decision to start the therapy should be evidencebased and rely on most recent guidelines supported by high quality evidence. Additionally, prescribing physicians should have an ongoing discussion with their patients and re-evaluation of their need to stay on PPI therapy. Working together with the patient, setting realistic expectations from the beginning,following evidence-based guidelines, and continuing to re-evaluate of need for therapy could increase patient satisfaction with medical care, provide reassurance, and help more people to safely benefit from PPI therapy.

    CONCLUSION

    Since their first introduction to the medical practice, PPIs have come a long way and we now know much more about their pharmacodynamics and side-effect profile. The side-effect data remains controversial with most recent ACG guidelines arguing against significant risks associated with this therapy.While data provided by ACG is reassuring, PPI therapy should still be utilized according to evidencebased practice. We now know more about which patients are more likely to benefit from this therapy and why some patients should only be on it short term. As our understanding of this therapy deepens,our practice should change to help more patients to safely benefit from PPIs. Following evidence-based guidelines and working together with a patient managing expectations and educating on risks may be the key to successful come back of PPI therapy.

    FOOTNOTES

    Author contributions:Turshudzhyan A, Samuel S, and Tawfik A wrote the manuscript; Tadros M revised the manuscript.

    Conflict-of-interest statement:There are no conflicts of interest to report.

    Open-Access:This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC ΒYNC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is noncommercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

    Country/Territory of origin:United States

    ORCID number:Alla Turshudzhyan 0000-0001-6867-7569; Sonia Samuel 0000-0003-3359-0222; Angela Tawfik 0000-0002-0001-8126; Micheal Tadros 0000-0003-3118-3893.

    S-Editor:Chen YL

    L-Editor:A

    P-Editor:Chen YL

    国产成人精品久久二区二区91| 午夜成年电影在线免费观看| 国产1区2区3区精品| 婷婷亚洲欧美| 欧美日本亚洲视频在线播放| 久久久久久久午夜电影| 18禁裸乳无遮挡免费网站照片| e午夜精品久久久久久久| 国产精品永久免费网站| 啦啦啦观看免费观看视频高清| 日日夜夜操网爽| 日本在线视频免费播放| 成人av在线播放网站| 1024手机看黄色片| 亚洲av电影在线进入| 久久精品影院6| 国产成人系列免费观看| 大型黄色视频在线免费观看| 亚洲av成人不卡在线观看播放网| 日韩欧美精品v在线| 男女下面进入的视频免费午夜| 99国产综合亚洲精品| 国产成人aa在线观看| 丰满人妻熟妇乱又伦精品不卡| 日日摸夜夜添夜夜添小说| 一级毛片精品| 女警被强在线播放| cao死你这个sao货| 男女午夜视频在线观看| 老汉色∧v一级毛片| 亚洲欧美精品综合一区二区三区| 欧美zozozo另类| 精品无人区乱码1区二区| 精品一区二区三区av网在线观看| 国产成人精品久久二区二区免费| 国内精品久久久久精免费| 欧美国产日韩亚洲一区| 又大又爽又粗| 国产成人精品久久二区二区91| 听说在线观看完整版免费高清| videosex国产| 国产私拍福利视频在线观看| 国内揄拍国产精品人妻在线| 国产av不卡久久| 国产成人影院久久av| 国产久久久一区二区三区| 岛国在线观看网站| 99久久精品热视频| 国产精华一区二区三区| 最新美女视频免费是黄的| 黄色a级毛片大全视频| 国内精品久久久久精免费| 1024手机看黄色片| 一边摸一边抽搐一进一小说| 97碰自拍视频| 午夜视频精品福利| 777久久人妻少妇嫩草av网站| 一本大道久久a久久精品| 亚洲一区中文字幕在线| 亚洲精品一卡2卡三卡4卡5卡| 日本黄大片高清| 日本黄大片高清| 动漫黄色视频在线观看| 我的老师免费观看完整版| av天堂在线播放| 久久久国产精品麻豆| 亚洲人与动物交配视频| 天天一区二区日本电影三级| 国产精品av视频在线免费观看| 啪啪无遮挡十八禁网站| 亚洲人成网站高清观看| 午夜福利高清视频| 亚洲av美国av| 久久久精品国产亚洲av高清涩受| 两性午夜刺激爽爽歪歪视频在线观看 | 国产视频一区二区在线看| 国产精品久久久人人做人人爽| 亚洲五月天丁香| 日本三级黄在线观看| 国产成+人综合+亚洲专区| 在线观看www视频免费| 黄色 视频免费看| 日韩精品中文字幕看吧| 久久精品国产综合久久久| 欧美最黄视频在线播放免费| 久久久久久久久中文| 韩国av一区二区三区四区| 成人国产综合亚洲| 日韩欧美 国产精品| 草草在线视频免费看| 这个男人来自地球电影免费观看| 啦啦啦韩国在线观看视频| 在线观看www视频免费| 亚洲片人在线观看| 九色成人免费人妻av| 九九热线精品视视频播放| 亚洲精品粉嫩美女一区| 岛国视频午夜一区免费看| videosex国产| 性色av乱码一区二区三区2| av超薄肉色丝袜交足视频| 国产欧美日韩一区二区精品| 亚洲国产精品国产精品| 国产精品综合久久久久久久免费| 国产精品女同一区二区软件| 别揉我奶头 嗯啊视频| 一级黄色大片毛片| 波多野结衣高清作品| 禁无遮挡网站| 精品99又大又爽又粗少妇毛片| 国产午夜精品一二区理论片| 久久亚洲国产成人精品v| 国产精品不卡视频一区二区| 免费观看人在逋| 黄色视频,在线免费观看| 少妇猛男粗大的猛烈进出视频 | 免费搜索国产男女视频| 老师上课跳d突然被开到最大视频| 国产伦理片在线播放av一区 | 国产精品av视频在线免费观看| 人人妻人人澡欧美一区二区| 国产真实伦视频高清在线观看| 国产极品天堂在线| 欧美日韩在线观看h| 少妇丰满av| 听说在线观看完整版免费高清| 国产精品久久久久久久久免| 白带黄色成豆腐渣| av国产免费在线观看| 国国产精品蜜臀av免费| 少妇裸体淫交视频免费看高清| 国产国拍精品亚洲av在线观看| 长腿黑丝高跟| 亚洲av男天堂| 国产av不卡久久| 日本av手机在线免费观看| 老司机福利观看| 国产高清不卡午夜福利| 亚洲精品色激情综合| 国产成人a∨麻豆精品| 热99re8久久精品国产| 日本一二三区视频观看| 禁无遮挡网站| 在线免费十八禁| 女人被狂操c到高潮| 国产在视频线在精品| 两性午夜刺激爽爽歪歪视频在线观看| 国产精品一及| 人妻少妇偷人精品九色| 亚洲三级黄色毛片| 欧美最新免费一区二区三区| 1000部很黄的大片| 成人亚洲欧美一区二区av| av在线蜜桃| 国产极品天堂在线| 一区福利在线观看| 亚洲精品国产成人久久av| 国产精品伦人一区二区| 亚洲成人久久性| 色综合站精品国产| 简卡轻食公司| 高清在线视频一区二区三区 | 国产精品日韩av在线免费观看| 国产成人福利小说| 国产黄a三级三级三级人| 91久久精品国产一区二区成人| 国产大屁股一区二区在线视频| 22中文网久久字幕| 国产av不卡久久| 亚洲va在线va天堂va国产| 美女高潮的动态| 99热精品在线国产| 日韩视频在线欧美| 国产成人a区在线观看| 国产激情偷乱视频一区二区| 两性午夜刺激爽爽歪歪视频在线观看| 成人毛片a级毛片在线播放| 精品国产三级普通话版| 有码 亚洲区| 亚洲欧美日韩卡通动漫| 国产精品野战在线观看| www.色视频.com| 简卡轻食公司| 国产成人一区二区在线| 国产亚洲5aaaaa淫片| 国产男人的电影天堂91| 久久久久久久午夜电影| 成人午夜高清在线视频| 日韩亚洲欧美综合| 亚洲国产精品国产精品| 黄色日韩在线| 亚洲精品久久久久久婷婷小说 | 久久精品91蜜桃| 噜噜噜噜噜久久久久久91| 国产精品久久电影中文字幕| 午夜福利高清视频| 97热精品久久久久久| 99久久精品一区二区三区| 国产精品福利在线免费观看| 欧美性猛交╳xxx乱大交人| 亚洲成人久久爱视频| 成年av动漫网址| 亚洲国产精品国产精品| 精品久久久久久久久久免费视频| kizo精华| 内射极品少妇av片p| 日韩一本色道免费dvd| 舔av片在线| 精品久久久久久久久久久久久| 看十八女毛片水多多多| 一级毛片久久久久久久久女| 99久久精品一区二区三区| avwww免费| 成人性生交大片免费视频hd| 高清午夜精品一区二区三区 | 亚洲在久久综合| 亚洲国产欧美在线一区| 直男gayav资源| 久久久午夜欧美精品| 中国美女看黄片| 国产精品人妻久久久久久| 国产精品久久久久久精品电影| 狂野欧美白嫩少妇大欣赏| 亚洲在久久综合| 久久精品国产自在天天线| or卡值多少钱| 久久综合国产亚洲精品| 亚洲精品国产av成人精品| 免费在线观看成人毛片| www.av在线官网国产| 欧美日韩在线观看h| 日日摸夜夜添夜夜爱| 亚洲av电影不卡..在线观看| 国产欧美日韩精品一区二区| 国产老妇女一区| 五月玫瑰六月丁香| 亚洲久久久久久中文字幕| 又粗又爽又猛毛片免费看| av卡一久久| a级一级毛片免费在线观看| 国产蜜桃级精品一区二区三区| 亚洲国产色片| 日韩成人伦理影院| 国产午夜精品久久久久久一区二区三区| 亚洲欧洲日产国产| 午夜老司机福利剧场| 亚洲久久久久久中文字幕| 可以在线观看毛片的网站| 人体艺术视频欧美日本| 精品人妻偷拍中文字幕| 亚洲一级一片aⅴ在线观看| 卡戴珊不雅视频在线播放| 夜夜夜夜夜久久久久| 免费av不卡在线播放| 淫秽高清视频在线观看| 成人二区视频| 老熟妇乱子伦视频在线观看| 久久国产乱子免费精品| or卡值多少钱| 国产亚洲av嫩草精品影院| 久久精品国产99精品国产亚洲性色| 一级毛片aaaaaa免费看小| 亚洲成人av在线免费| 美女大奶头视频| 18禁裸乳无遮挡免费网站照片| 赤兔流量卡办理| 黄片wwwwww| 高清毛片免费观看视频网站| 级片在线观看| 日韩大尺度精品在线看网址| 免费看光身美女| 在线观看66精品国产| 亚洲乱码一区二区免费版| av在线天堂中文字幕| 免费看日本二区| 插逼视频在线观看| 少妇猛男粗大的猛烈进出视频 | or卡值多少钱| 精品久久久噜噜| 国产精品福利在线免费观看| 夜夜爽天天搞| 又爽又黄a免费视频| 在线国产一区二区在线| 三级国产精品欧美在线观看| 日韩制服骚丝袜av| 卡戴珊不雅视频在线播放| 老师上课跳d突然被开到最大视频| 尾随美女入室| 国产一区二区三区av在线 | 欧美一区二区精品小视频在线| 午夜老司机福利剧场| 国内精品一区二区在线观看| 亚洲七黄色美女视频| 美女被艹到高潮喷水动态| 亚洲乱码一区二区免费版| 欧美性猛交╳xxx乱大交人| 国产日本99.免费观看| 欧美极品一区二区三区四区| 日韩,欧美,国产一区二区三区 | 人体艺术视频欧美日本| 国产一区二区在线观看日韩| 久久综合国产亚洲精品| 99在线视频只有这里精品首页| 日本一本二区三区精品| 日产精品乱码卡一卡2卡三| 99国产精品一区二区蜜桃av| 麻豆成人av视频| 国产精品三级大全| 啦啦啦观看免费观看视频高清| 久久精品夜夜夜夜夜久久蜜豆| 99久国产av精品国产电影| 小蜜桃在线观看免费完整版高清| 国产一级毛片七仙女欲春2| 久久久久久久久大av| a级毛片a级免费在线| 国产成人aa在线观看| 美女被艹到高潮喷水动态| 亚洲av中文av极速乱| 嫩草影院新地址| 极品教师在线视频| 欧美最新免费一区二区三区| 国产精品一区二区三区四区久久| 国产又黄又爽又无遮挡在线| 亚洲欧洲国产日韩| 一卡2卡三卡四卡精品乱码亚洲| 亚洲欧美精品自产自拍| 免费看美女性在线毛片视频| 成熟少妇高潮喷水视频| 看片在线看免费视频| 亚洲经典国产精华液单| www.色视频.com| 欧美zozozo另类| 99久国产av精品| 国产精品99久久久久久久久| 成人三级黄色视频| 精品人妻熟女av久视频| 日韩av不卡免费在线播放| 亚洲国产色片| 天天躁夜夜躁狠狠久久av| 在现免费观看毛片| 国产免费一级a男人的天堂| 美女cb高潮喷水在线观看| 免费av不卡在线播放| 午夜亚洲福利在线播放| 国产精品麻豆人妻色哟哟久久 | 久久中文看片网| 美女内射精品一级片tv| 国内久久婷婷六月综合欲色啪| 精品少妇黑人巨大在线播放 | 丝袜喷水一区| 色视频www国产| 国产av麻豆久久久久久久| 22中文网久久字幕| 乱人视频在线观看| 老司机福利观看| а√天堂www在线а√下载| 天堂影院成人在线观看| ponron亚洲| 亚洲无线在线观看| 亚洲成a人片在线一区二区| 一个人看的www免费观看视频| 看非洲黑人一级黄片| 日韩欧美精品免费久久| 人人妻人人看人人澡| 久久久成人免费电影| 99久久人妻综合| 久久久成人免费电影| 99久久人妻综合| 日韩欧美一区二区三区在线观看| 少妇人妻精品综合一区二区 | 日本免费一区二区三区高清不卡| 噜噜噜噜噜久久久久久91| 日韩一区二区三区影片| 国产伦理片在线播放av一区 | 爱豆传媒免费全集在线观看| 亚洲国产色片| 日韩欧美在线乱码| 看非洲黑人一级黄片| 国产老妇伦熟女老妇高清| 国产精品一区二区三区四区免费观看| 一个人观看的视频www高清免费观看| 成人高潮视频无遮挡免费网站| 一区二区三区四区激情视频 | 在线免费观看的www视频| 久久精品夜色国产| 国产免费男女视频| 亚洲欧美成人综合另类久久久 | 国产成人福利小说| 婷婷色av中文字幕| 国产熟女欧美一区二区| 99在线人妻在线中文字幕| 成年免费大片在线观看| 在线观看免费视频日本深夜| 亚洲欧美清纯卡通| 成人毛片a级毛片在线播放| 国产黄色视频一区二区在线观看 | 久久精品综合一区二区三区| 尾随美女入室| 欧美在线一区亚洲| 老熟妇乱子伦视频在线观看| 一本久久精品| 两个人的视频大全免费| 日韩 亚洲 欧美在线| 日韩精品青青久久久久久| 久久久久性生活片| 黄片wwwwww| 日本三级黄在线观看| 久久久久久伊人网av| 国产成人精品一,二区 | 黄色一级大片看看| 久久午夜福利片| 欧美日韩综合久久久久久| 国产精华一区二区三区| 91久久精品电影网| 美女高潮的动态| 亚洲精品成人久久久久久| 欧洲精品卡2卡3卡4卡5卡区| 国产精品,欧美在线| 国产成人精品一,二区 | 夫妻性生交免费视频一级片| 一本一本综合久久| 亚洲精品自拍成人| 国产一级毛片在线| 婷婷六月久久综合丁香| 亚洲在线观看片| 中文精品一卡2卡3卡4更新| 看片在线看免费视频| av在线天堂中文字幕| 久久久久国产网址| 国模一区二区三区四区视频| 亚洲成人久久性| 狂野欧美白嫩少妇大欣赏| 亚洲乱码一区二区免费版| 成人亚洲精品av一区二区| 久久久久久伊人网av| 成人综合一区亚洲| 激情 狠狠 欧美| 国产免费男女视频| 亚洲精品久久国产高清桃花| 欧美一区二区精品小视频在线| 人妻系列 视频| 亚洲国产精品sss在线观看| 九九爱精品视频在线观看| 91麻豆精品激情在线观看国产| av黄色大香蕉| 色噜噜av男人的天堂激情| 色视频www国产| 欧美精品一区二区大全| 亚洲av一区综合| 国产日本99.免费观看| 日本熟妇午夜| or卡值多少钱| 又黄又爽又刺激的免费视频.| 亚洲一区二区三区色噜噜| av卡一久久| 亚洲国产高清在线一区二区三| 久久久久九九精品影院| 变态另类成人亚洲欧美熟女| 欧美成人a在线观看| 午夜福利在线观看免费完整高清在 | 亚洲最大成人av| 亚洲人成网站在线观看播放| 成人午夜高清在线视频| 日本-黄色视频高清免费观看| 亚洲欧美中文字幕日韩二区| 午夜福利在线观看免费完整高清在 | 欧美最新免费一区二区三区| 一区二区三区免费毛片| 12—13女人毛片做爰片一| 美女 人体艺术 gogo| 日韩欧美精品v在线| 亚洲第一电影网av| 亚洲精品粉嫩美女一区| 亚洲欧美日韩东京热| 久久午夜福利片| 国产高潮美女av| 久久久国产成人精品二区| 久久婷婷人人爽人人干人人爱| 久久久久久久亚洲中文字幕| 亚洲精品国产成人久久av| 成人高潮视频无遮挡免费网站| 一本久久精品| 2022亚洲国产成人精品| 欧美高清性xxxxhd video| 亚州av有码| 中文字幕av在线有码专区| av视频在线观看入口| 99视频精品全部免费 在线| 成人av在线播放网站| 日本与韩国留学比较| 国产精品久久电影中文字幕| 99在线人妻在线中文字幕| 欧美人与善性xxx| 亚洲婷婷狠狠爱综合网| 22中文网久久字幕| 欧美极品一区二区三区四区| 国产亚洲91精品色在线| 精品少妇黑人巨大在线播放 | 男女那种视频在线观看| 国产精品精品国产色婷婷| 免费无遮挡裸体视频| 午夜精品在线福利| 亚洲欧美日韩无卡精品| 又黄又爽又刺激的免费视频.| 激情 狠狠 欧美| 波野结衣二区三区在线| 能在线免费观看的黄片| 少妇丰满av| 成人美女网站在线观看视频| 美女xxoo啪啪120秒动态图| 国语自产精品视频在线第100页| 好男人在线观看高清免费视频| 黄片无遮挡物在线观看| 国产色爽女视频免费观看| 乱人视频在线观看| 国产老妇女一区| 一级黄片播放器| 久久99热这里只有精品18| 美女被艹到高潮喷水动态| 一区二区三区四区激情视频 | 日本撒尿小便嘘嘘汇集6| 精品国产三级普通话版| 国产激情偷乱视频一区二区| а√天堂www在线а√下载| 全区人妻精品视频| 特大巨黑吊av在线直播| 久久人人精品亚洲av| 久久草成人影院| 日韩精品有码人妻一区| 人妻系列 视频| 男人舔奶头视频| 久99久视频精品免费| 国内少妇人妻偷人精品xxx网站| 日韩亚洲欧美综合| 久久精品91蜜桃| 春色校园在线视频观看| 国产精品99久久久久久久久| 欧美性猛交╳xxx乱大交人| 久久久欧美国产精品| 亚州av有码| 日本一本二区三区精品| 免费av毛片视频| 一卡2卡三卡四卡精品乱码亚洲| 精品国产三级普通话版| 色尼玛亚洲综合影院| 亚洲美女视频黄频| 国产av一区在线观看免费| 国产伦精品一区二区三区视频9| 久久精品国产亚洲网站| 亚洲成人久久性| 男插女下体视频免费在线播放| av天堂中文字幕网| 精品免费久久久久久久清纯| 国产在线男女| 男女边吃奶边做爰视频| 青春草视频在线免费观看| av免费在线看不卡| 一本精品99久久精品77| 国产伦精品一区二区三区视频9| 国产69精品久久久久777片| 神马国产精品三级电影在线观看| 国产成人aa在线观看| 男女啪啪激烈高潮av片| 色视频www国产| 免费观看a级毛片全部| 国产在视频线在精品| 色哟哟·www| 欧美最新免费一区二区三区| 青春草国产在线视频 | 亚洲成人久久爱视频| 久久99热这里只有精品18| 日韩成人伦理影院| 亚洲av免费高清在线观看| 久久精品国产自在天天线| 欧美变态另类bdsm刘玥| 国产成人影院久久av| 亚洲成人精品中文字幕电影| 亚洲人成网站高清观看| 亚洲av熟女| 日本免费一区二区三区高清不卡| 蜜桃久久精品国产亚洲av| 舔av片在线| 亚洲国产高清在线一区二区三| 中出人妻视频一区二区| 久久久久久国产a免费观看| www.av在线官网国产| 麻豆成人午夜福利视频| 国内揄拍国产精品人妻在线| 97超碰精品成人国产| 亚洲精品影视一区二区三区av| 日本-黄色视频高清免费观看| 人妻少妇偷人精品九色| 国产精品无大码| 亚洲美女搞黄在线观看| 自拍偷自拍亚洲精品老妇| 久久久国产成人免费| 国产高潮美女av| 精品人妻熟女av久视频| 神马国产精品三级电影在线观看| 日本撒尿小便嘘嘘汇集6| 亚洲欧美日韩无卡精品| 女的被弄到高潮叫床怎么办| 午夜a级毛片| 日韩欧美国产在线观看| 色吧在线观看| 精品久久久久久久人妻蜜臀av| 激情 狠狠 欧美| 看十八女毛片水多多多| 一边摸一边抽搐一进一小说| 欧美三级亚洲精品| 在线免费十八禁| 国产乱人视频| 亚洲一区高清亚洲精品| 亚洲精品成人久久久久久| 欧美另类亚洲清纯唯美|